LENZ Therapeutics, Inc.
No enriched coverage for $LENZ in the last 7 days.
No SEC Form 4 filings for $LENZ in the last 30 days.
See all $LENZ insider activity →LENZ Therapeutics reported Q2 2026 revenue of $5.5M, with product revenue up 9% QoQ. Prescription growth surged 45% in July, driven by telehealth and advertising. Net loss was $31.9M, with $220M in cash reserves. The company highlighted strong patient persistence and global partnerships.
Lenz Therapeutics reported Q2 2026 revenue of $5.5 million, including $3.8 million in license revenue tied to regulatory and sublicense milestones in Canada and Greater China. Management said July prescriptions rose 45% month over month after a national TV campaign and a telehealth access pathway. The company expects direct gross margins near 90% over time and continued international expansion.
LENZ Therapeutics shares rose about 7.7% pre-open after the company reported Q2 2026 results Aug. 11. Revenue was $5.5M vs about $2.5M expected. EPS loss was $1.02 vs $1.07 expected. Product revenue was $1.7M and license revenue $3.8M. VIZZ prescriptions rose 45% in July. Citi reiterated Buy but cut its target to $10 from $20.
Recent LENZ coverage spans earnings, financial news and corporate actions.
LENZ posted modest revenue growth but a sizable net loss, indicating heavy marketing spend and cash runway.
Telehealth plus TV-driven demand appears to be improving conversion and persistence, but Q3 will determine which commercial levers deliver the best ROI.
The stock move is driven by a sizable Q2 revenue beat and improving commercial traction (VIZZ packs and prescriptions), plus a less-bullish but still positive Citi stance.
The 8-K provides fresh commercial traction metrics (packs, refill behavior, prescriber uptake) plus cash and expense updates, shaping near-term sentiment and risk.
Telehealth + TV/digital DTC promotion is a new go-to-market channel that could accelerate VIZZ adoption and improve access, supporting near-term sales expectations.
AlphAI scores every news story that mentions LENZ with an AI model for sentiment and relevance, and aggregates insider trades from LENZ Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LENZ Therapeutics reported Q2 2026 revenue of $5.5M, with product revenue up 9% QoQ. Prescription growth surged 45% in July, driven by telehealth and advertising. Net loss was $31.9M, with $220M in cash reserves. The company highlighted strong patient persistence and global partnerships.
3 min readLenz Therapeutics reported Q2 2026 revenue of $5.5 million, including $3.8 million in license revenue tied to regulatory and sublicense milestones in Canada and Greater China. Management said July prescriptions rose 45% month over month after a national TV campaign and a telehealth access pathway. The company expects direct gross margins near 90% over time and continued international expansion.
7 min readLENZ Therapeutics shares rose about 7.7% pre-open after the company reported Q2 2026 results Aug. 11. Revenue was $5.5M vs about $2.5M expected. EPS loss was $1.02 vs $1.07 expected. Product revenue was $1.7M and license revenue $3.8M. VIZZ prescriptions rose 45% in July. Citi reiterated Buy but cut its target to $10 from $20.
4 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy
6 min readLENZ Therapeutics (Nasdaq: LENZ) said VIZZ (aceclidine ophthalmic solution) 1.44% is now available via a telehealth platform at VIZZ.com, adding online eligibility evaluation by licensed eye care providers, e-pharmacy fulfillment, and home delivery. LENZ plans to promote the channel with a national TV campaign featuring Sarah Jessica Parker.
4 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. lenz-20260630 FALSE 0001815776 Solana Beach California 0001815776 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
2 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. lenz-20260612 FALSE 0001815776 Solana Beach California 0001815776 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
2 min readLENZ Therapeutics (NASDAQ:LENZ) recently released its yearly report, revealing revenues of US$19m, missing analyst predictions, and a statutory loss of US$2.85 per share, exceeding forecasts. Analysts have since cut next year's revenue estimates to US$30.3m and increased loss per share forecasts to US$3.62, leading to a 13% drop in the consensus price target to US$44.43. Despite the downgraded outlook, the company is still expected to experience revenue growth significantly faster than the broader industry.
3 min readWall Street Zen has downgraded LENZ Therapeutics (NASDAQ:LENZ) from a "hold" to a "sell" rating. This follows a similar downgrade by Weiss Ratings, although the consensus among analysts still rates the stock as a "Moderate Buy" with an average target price of $56.40. The article also details the company's stock performance, institutional investor holdings, and company profile.
3 min readLENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min read
